Carnosine / toxicity Cancer Research Results

Carno, Carnosine: Click to Expand ⟱
Features:

Carnosine (CAR; β-alanyl-L-histidine) is an endogenous dipeptide and dietary supplement (high in meat; also synthesized).
Primary mechanisms (conceptual rank):
1) Carbonyl/aldehyde scavenging + anti-glycation (AGE) suppression → proteostasis stress ↓ (P/R)
2) Cancer metabolism interference (Warburg/glycolysis pressure) → proliferation ↓ (model-dependent; often high concentration) (R/G)
3) Metal chelation + ROS/RNS buffering (secondary redox modulation) (P/R; context-dependent)
Bioavailability / PK: Orally absorbed, but rapidly hydrolyzed in human blood by carnosinase (CN1) → very short circulating half-life; sustained systemic CAR exposure is limited vs β-alanine/histidine metabolites.
In-vitro vs realistic exposure: Many anti-proliferative / glycolysis effects are reported at high µM–mM CAR in vitro, commonly exceeding realistic systemic CAR exposure due to rapid serum hydrolysis.
Clinical evidence status (cancer): Predominantly preclinical for direct anti-cancer effects; human oncology evidence is mainly adjunct/supportive (e.g., zinc-L-carnosine for radiation-related symptoms), not established as an anti-tumor monotherapy.

L-Carnosine (usually just called "Carnosine") is a naturally occurring dipeptide composed of L-histidine and β-alanine, found in high concentrations in muscle and brain tissue.
-Source: only found in animals Beef(372mg/100g), ChickenBreast(290mg/100g), Pork(276mg/100g), TurkeyBreast(240mg/100g)
-Anserine is a derivative of carnosine
-Scavenges reactive oxygen species (ROS)
-Inhibits formation of AGEs (advanced glycation end-products), which are linked to aging and neurodegeneration.
-Metal chelator: Binds excess zinc, copper, and iron—important in brain health.


Carnosine (CAR) — Pathway / Axis Effects (Cancer vs Normal)

Rank Pathway / Axis Cancer Cells (↑ / ↓ / ↔) Normal Cells (↑ / ↓ / ↔) TSF Primary Effect Notes / Interpretation
1 Carbonyl stress / anti-glycation (AGE) ↓ proteotoxic/carbonyl stress (context-dependent) ↓ glycation damage (protective) P/R Cell stress buffering Core “chemoprotective” chemistry: nucleophilic scavenging of reactive carbonyls; cancer-direction depends on whether tumor relies on carbonyl-stress adaptation.
2 Warburg / glycolysis pressure ↓ glycolysis flux (model-dependent; high concentration only) ↔ R/G Anti-proliferative (subset) Frequently reported in vitro with supraphysiologic CAR; translation constrained by rapid serum hydrolysis in humans.
3 Mitochondrial function / energetic stress ↔ / ↑ energetic stress (model-dependent) ↔ / protective (context-dependent) R Growth suppression vs resilience Direction varies by baseline metabolic state and substrate availability; often secondary to carbonyl/redox effects.
4 ROS ↓ ROS (secondary; context-dependent) ↓ oxidative damage (protective) P/R Redox buffering Typically described as antioxidant buffering; paradoxical “ROS ↑” cytotoxicity is not a dominant CAR narrative.
5 NRF2 (stress-response axis) ↔ / ↑ cytoprotection (context-dependent; resistance risk) ↔ / ↑ protective G Adaptive stress signaling If NRF2 is already oncogenic (e.g., KEAP1/NFE2L2-altered tumors), further cytoprotection could be undesirable.
6 Ca²⁺ (ER/mitochondria stress coupling) ↔ (not primary; model-dependent) ↔ R Stress modulation (secondary) Include only as a secondary axis: CAR’s dominant reported levers are carbonyl/redox/metabolic rather than direct Ca²⁺ channel control.
7 Ferroptosis ↔ (context-dependent) ↔ R/G Unclear / secondary CAR’s anti-lipid-peroxidation tendency could oppose ferroptosis in some contexts; evidence is not central vs carbonyl/AGE chemistry.
8 Clinical Translation Constraint Human systemic CAR exposure is constrained by rapid serum hydrolysis (CN1); much in-vitro anti-cancer work uses high µM–mM. Strongest human oncology signal is adjunct/supportive use (e.g., zinc-L-carnosine symptom prevention), not proven tumor regression. — PK-limited; adjunct-only Consider delivery strategies/analogs (e.g., carnosinase-resistant histidine dipeptides) if pursuing systemic pharmacology.

TSF legend: P: 0–30 min (primary/rapid effects; direct enzyme/redox interactions) · R: 30 min–3 hr (acute signaling + stress responses) · G: >3 hr (gene-regulatory adaptation; phenotype outcomes)
toxicity, toxicity: Click to Expand ⟱
Source:
Type:
Toxicity
Scientific Papers found: Click to Expand⟱
3869- Carno,    Carnosine, Small but Mighty—Prospect of Use as Functional Ingredient for Functional Food Formulation
- Review, AD, NA - Review, Stroke, NA
*ROS↓, *IronCh↑, *AntiAge↑, *antiOx↑, *Inflam↓, *neuroP↑, *lipid-P↓, *toxicity↓, *NOX4↓, *SOD↑, *HNE↓, *IL6↓, *TNF-α↓, *IL1β↓, *Sepsis↓, *eff↑, *GABA↝, *Aβ↓, Glycolysis↓, AntiTum↑, p‑Akt↓, TumCCA↑, angioG↓, VEGFR2↓, NF-kB↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Core Metabolism/Glycolysis ⓘ

Glycolysis↓, 1,  

Cell Death ⓘ

p‑Akt↓, 1,  

Cell Cycle & Senescence ⓘ

TumCCA↑, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   VEGFR2↓, 1,  

Immune & Inflammatory Signaling ⓘ

NF-kB↓, 1,  

Functional Outcomes ⓘ

AntiTum↑, 1,  
Total Targets: 7

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   HNE↓, 1,   lipid-P↓, 1,   NOX4↓, 1,   ROS↓, 1,   SOD↑, 1,  

Metal & Cofactor Biology ⓘ

IronCh↑, 1,  

Immune & Inflammatory Signaling ⓘ

IL1β↓, 1,   IL6↓, 1,   Inflam↓, 1,   TNF-α↓, 1,  

Synaptic & Neurotransmission ⓘ

GABA↝, 1,  

Protein Aggregation ⓘ

Aβ↓, 1,  

Drug Metabolism & Resistance ⓘ

eff↑, 1,  

Clinical Biomarkers ⓘ

IL6↓, 1,  

Functional Outcomes ⓘ

AntiAge↑, 1,   neuroP↑, 1,   toxicity↓, 1,  

Infection & Microbiome ⓘ

Sepsis↓, 1,  
Total Targets: 19

Scientific Paper Hit Count for: toxicity, toxicity
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:351  Target#:1025  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page